<p>Design Therapeutics, Inc.（纳斯达克代码：DSGN - 获取免费报告）的股票获得了目前覆盖该公司的五家评级机构的共识推荐，评级为 “适度买入”，MarketBeat.com 报道。一位研究分析师对该股票给予了卖出评级，三位分析师给予了买入评级，还有一位分析师给予了强烈买入评级。在过去一年中，更新了对该股票覆盖的券商的平均一年目标价为 14.00 美元。</p>
<p>多家研究机构最近对 DSGN 进行了评估。加拿大皇家银行在 11 月 20 日的研究报告中将 Design Therapeutics 的股票评级从 “行业表现” 上调至 “跑赢大盘”，并将其目标价从 6.00 美元提高至 13.00 美元。Leerink Partners 在周三的研究报告中将 Design Therapeutics 的评级从 “持有” 上调至 “强烈买入”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Design Therapeutics 股票的 “卖出（d-）” 评级。Craig Hallum 在周三开始对 Design Therapeutics 进行覆盖，并为该公司设定了 “买入” 评级和 15.00 美元的目标价。最后，华尔街 Zen 在 11 月 8 日的研究报告中将 Design Therapeutics 的股票评级从 “卖出” 上调至 “持有”。</p>
<p>获取 <strong>Design Therapeutics</strong> 的提醒：</p>
<p><strong>阅读我们最新的 DSGN 股票分析</strong></p>
<h2>机构投资者对 Design Therapeutics 的看法</h2>
<p>几家机构投资者最近增加或减少了对该公司的持股。美国银行在第二季度将其在 Design Therapeutics 的股份增加了 11.1%。美国银行目前拥有 24,625 股该公司的股票，价值 83,000 美元，此前在上个季度购买了 2,459 股。拉塞尔投资集团在第三季度将其在 Design Therapeutics 的股份增加了 69.6%。拉塞尔投资集团目前拥有 6,377 股该公司的股票，价值 48,000 美元，此前在上个季度购买了 2,618 股。景顺公司在第二季度将其在 Design Therapeutics 的股份增加了 26.8%。景顺公司目前拥有 14,364 股该公司的股票，价值 48,000 美元，此前在上个季度购买了 3,033 股。MPM Bioimpact LLC 在第一季度将其在 Design Therapeutics 的股份增加了 0.6%。MPM Bioimpact LLC 目前拥有 562,943 股该公司的股票，价值 2,173,000 美元，此前在上个季度购买了 3,396 股。最后，摩根大通在第三季度将其在 Design Therapeutics 的股份增加了 26.7%。摩根大通目前拥有 23,221 股该公司的股票，价值 175,000 美元，此前在上个季度购买了 4,896 股。对冲基金和其他机构投资者持有该公司 56.64% 的股份。</p>
<h2>Design Therapeutics 股价上涨 9.3%</h2>
<p>周四，DSGN 股票开盘价为 9.77 美元。Design Therapeutics 的 12 个月低点为 2.60 美元，12 个月高点为 10.00 美元。该公司的 50 日移动平均线为 7.14 美元，200 日移动平均线为 5.44 美元。该公司的市值为 5.565 亿美元，市盈率为-8.21，贝塔值为 1.63。</p>
<p>Design Therapeutics（纳斯达克代码：DSGN - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告的每股收益为（0.30 美元），超过了市场共识预期的（0.34 美元）0.04 美元。研究分析师平均预测，Design Therapeutics 在当前财政年度的每股收益将为-0.91。</p>
<h2>Design Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Design Therapeutics, Inc 是一家生物制药公司，专注于研究、设计、开发和商业化小分子治疗药物，以治疗美国的遗传疾病。该公司利用其 GeneTAC 平台设计和开发因核苷酸重复扩展引起的遗传疾病的治疗候选药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Design Therapeutics</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>MongoDB 刚刚发布了超预期的季度财报——但它是否过热？</li>
<li>什么是标准普尔 500 指数，它与其他指数有何不同</li>
<li>三只有望受益于谷歌 AI 突破的股票</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>超越 NVIDIA：五只有望主导 2026 年的半导体股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Design Therapeutics 吗？</h2>
<p>在考虑投资 Design Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Design Therapeutics 并不在名单上。</p>
<p>虽然 Design Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

DSGN

<p>Design Therapeutics, Inc.（纳斯达克代码：DSGN）获得了五家券商的共识 “适度买入” 评级，平均目标价为 14.00 美元。加拿大皇家银行将该股票评级上调至 “跑赢大盘”，并将目标价提高至 13.00 美元。机构投资者已调整其持股，摩根大通和美国银行增加了其持仓。该股票目前交易价格为 9.77 美元，市值为 5.565 亿美元。公司报告的季度收益好于预期，每股收益为（0.30 美元）</p>

<p>Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $14.00.</p>
<div class="lb-trans"><p>Design Therapeutics, Inc.（纳斯达克代码：DSGN - 获取免费报告）的股票获得了目前覆盖该公司的五家评级机构的共识推荐，评级为 “适度买入”，MarketBeat.com 报道。一位研究分析师对该股票给予了卖出评级，三位分析师给予了买入评级，还有一位分析师给予了强烈买入评级。在过去一年中，更新了对该股票覆盖的券商的平均一年目标价为 14.00 美元。</p>
</div><p>A number of research firms recently weighed in on DSGN. Royal Bank Of Canada raised shares of Design Therapeutics from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the stock from $6.00 to $13.00 in a research report on Thursday, November 20th. Leerink Partnrs upgraded Design Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Wednesday. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Design Therapeutics in a report on Wednesday, October 8th. Craig Hallum started coverage on Design Therapeutics in a report on Wednesday. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Wall Street Zen upgraded shares of Design Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th.</p>
<div class="lb-trans"><p>多家研究机构最近对 DSGN 进行了评估。加拿大皇家银行在 11 月 20 日的研究报告中将 Design Therapeutics 的股票评级从 “行业表现” 上调至 “跑赢大盘”，并将其目标价从 6.00 美元提高至 13.00 美元。Leerink Partners 在周三的研究报告中将 Design Therapeutics 的评级从 “持有” 上调至 “强烈买入”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Design Therapeutics 股票的 “卖出（d-）” 评级。Craig Hallum 在周三开始对 Design Therapeutics 进行覆盖，并为该公司设定了 “买入” 评级和 15.00 美元的目标价。最后，华尔街 Zen 在 11 月 8 日的研究报告中将 Design Therapeutics 的股票评级从 “卖出” 上调至 “持有”。</p>
</div><p>Get <strong>Design Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Design Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Stock Analysis on DSGN</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 DSGN 股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Design Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Design Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its position in shares of Design Therapeutics by 11.1% in the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock valued at $83,000 after buying an additional 2,459 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Design Therapeutics by 69.6% in the third quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company's stock valued at $48,000 after acquiring an additional 2,618 shares in the last quarter. Invesco Ltd. boosted its stake in Design Therapeutics by 26.8% in the second quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after acquiring an additional 3,033 shares in the last quarter. MPM Bioimpact LLC grew its holdings in shares of Design Therapeutics by 0.6% during the first quarter. MPM Bioimpact LLC now owns 562,943 shares of the company's stock worth $2,173,000 after purchasing an additional 3,396 shares during the last quarter. Finally, JPMorgan Chase &amp; Co. increased its position in shares of Design Therapeutics by 26.7% during the third quarter. JPMorgan Chase &amp; Co. now owns 23,221 shares of the company's stock worth $175,000 after purchasing an additional 4,896 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了对该公司的持股。美国银行在第二季度将其在 Design Therapeutics 的股份增加了 11.1%。美国银行目前拥有 24,625 股该公司的股票，价值 83,000 美元，此前在上个季度购买了 2,459 股。拉塞尔投资集团在第三季度将其在 Design Therapeutics 的股份增加了 69.6%。拉塞尔投资集团目前拥有 6,377 股该公司的股票，价值 48,000 美元，此前在上个季度购买了 2,618 股。景顺公司在第二季度将其在 Design Therapeutics 的股份增加了 26.8%。景顺公司目前拥有 14,364 股该公司的股票，价值 48,000 美元，此前在上个季度购买了 3,033 股。MPM Bioimpact LLC 在第一季度将其在 Design Therapeutics 的股份增加了 0.6%。MPM Bioimpact LLC 目前拥有 562,943 股该公司的股票，价值 2,173,000 美元，此前在上个季度购买了 3,396 股。最后，摩根大通在第三季度将其在 Design Therapeutics 的股份增加了 26.7%。摩根大通目前拥有 23,221 股该公司的股票，价值 175,000 美元，此前在上个季度购买了 4,896 股。对冲基金和其他机构投资者持有该公司 56.64% 的股份。</p>
</div><h2>Design Therapeutics Trading Up 9.3%</h2>
<div class="lb-trans"><h2>Design Therapeutics 股价上涨 9.3%</h2>
</div><p>Shares of DSGN stock opened at $9.77 on Thursday. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $10.00. The business's 50 day moving average is $7.14 and its two-hundred day moving average is $5.44. The company has a market capitalization of $556.50 million, a P/E ratio of -8.21 and a beta of 1.63.</p>
<div class="lb-trans"><p>周四，DSGN 股票开盘价为 9.77 美元。Design Therapeutics 的 12 个月低点为 2.60 美元，12 个月高点为 10.00 美元。该公司的 50 日移动平均线为 7.14 美元，200 日移动平均线为 5.44 美元。该公司的市值为 5.565 亿美元，市盈率为-8.21，贝塔值为 1.63。</p>
</div><p>Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. On average, research analysts predict that Design Therapeutics will post -0.91 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Design Therapeutics（纳斯达克代码：DSGN - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告的每股收益为（0.30 美元），超过了市场共识预期的（0.34 美元）0.04 美元。研究分析师平均预测，Design Therapeutics 在当前财政年度的每股收益将为-0.91。</p>
</div><h2>Design Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Design Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.</p>
<div class="lb-trans"><p>Design Therapeutics, Inc 是一家生物制药公司，专注于研究、设计、开发和商业化小分子治疗药物，以治疗美国的遗传疾病。该公司利用其 GeneTAC 平台设计和开发因核苷酸重复扩展引起的遗传疾病的治疗候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Design Therapeutics</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Design Therapeutics</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>MongoDB 刚刚发布了超预期的季度财报——但它是否过热？</li>
<li>什么是标准普尔 500 指数，它与其他指数有何不同</li>
<li>三只有望受益于谷歌 AI 突破的股票</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>超越 NVIDIA：五只有望主导 2026 年的半导体股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DSGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Design Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Design Therapeutics 吗？</h2>
</div><p>Before you consider Design Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Design Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Design Therapeutics 并不在名单上。</p>
</div><p>While Design Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Design Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Design Therapeutics, Inc.（纳斯达克股票代码：DSGN）被券商给予 “适度买入” 的平均评级